|
Longitudinal changes in echocardiographic variables and endothelial function to predict cardiovascular toxicities in patients with multiple myeloma receiving carfilzomib. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Abbvie (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - BMS GmbH & Co. KG |
|
|
No Relationships to Disclose |
|
|
Honoraria - OncLive/MJH Life Sciences; Plexus |
Consulting or Advisory Role - Cota Healthcare; Janssen Scientific Affairs; Sanofi/Aventis |
Other Relationship - Bristol-Myers Squibb/Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |